CYP2C19基因多态性与阿那曲唑治疗绝经后乳腺癌患者疗效的相关性

Association of CYP2C19 gene polymorphism with anastrozole in treatment of postmenopausal breast cancer patients

目的探讨绝经后乳腺癌患者CYP2C19*2基因多态性与阿那曲唑疗效的相关性。方法采用PCR法检测绝经后乳腺癌患者和绝经后健康志愿者的基因多态性,术后给予阿那曲唑治疗。治疗后第4、12周检测FSH、LH水平、记录不良反应情况及随访5年无病生存情况。结果 A等位基因频率(OR=3.146,95%CI:1.244~7.275,P<0.05)是影响绝经后乳腺癌患者疗效的危险因素,AA和GA型的5年无病生存率低于GG型(χ~2=6.26,P<0.05),GG型患者的FSH、LH明显低于AA和GA型(t=5.29,6.47,P<0.05)。多因素Logistic回归分析显示,阿那曲唑和CYP2C19*2基因多态性均与绝经后乳腺癌患者的血清FSH、LH水平独立相关。结论 CYP2C19*2基因多态性与阿那曲唑可影响绝经后乳腺癌患者的临床疗效。

Objective To investigate the correlation between CYP2C 19＊2 gene polymorphism and efficacy of anastrozole in postmenopausal women with breast cancer. Methods The polymorphisms of CYP2C19＊2 gene in postmcnopausal women with postmenopausal breast cancer were detected by PCR. Results The A allele frequency of the CYP2C19＊2 gene （OR = 3.146, 95%CI： 1.244 - 7.275, P 〈 0.05） was a risk factor for the efficacy of post- menopausal breast cancer patients. The survival rate was lower than that of GG （χ^2= 6.26, P 〈 0.05 ）. After treatment, the FSH and LH of GG patients were significantly lower than those of AA and GA （t = 5.29, 6.47, P 〈0.05）. Multivariate logistic regression analysis showed that anastrozoleand CYP2C19＊2 gene polymorphism were independently associated with serum FSH and LH levels in postmenopausal women with breast. Conclusion CYP2C19＊2 gene polymorphism is associated with anastrozole in the treatment of postmenopausal breast cancer.